MedTrace Logo

IVIG/Rituximab vs Rituximab in Kidney Transplant With de Novo Donor-specific Antibodies

NCT04033276 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2022-10-26

No results posted yet for this study

Summary

The objective of this study was to compare two strategies of de novo donor specific antibodies (DSA) and antibody-mediated rejection (AMR) prevention in renal transplant recipients: high dose intravenous immunoglobulin (IVIG)/rituximab regimens versus rituximab alone.

Conditions

  • Renal Transplant

Interventions

DRUG

Rituximab

IV rituximab

DRUG

intravenous immune globulin

iv intravenous immune globulin

Sponsors & Collaborators

  • Severance Hospital

    collaborator OTHER

  • GC Biopharma Corp

    collaborator INDUSTRY

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Jaeseok Yang, M.D., Ph.D. · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-08
Primary Completion
2021-12-31
Completion
2022-05-03

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04033276 on ClinicalTrials.gov